The research will involve the application of GeneCentric's advanced RNA-based molecular profiling platform to elucidate potential signatures of disease progression and drug response to standard of care therapy, including the role of genomic alterations in the fibroblast growth factor receptor. Financial terms were not disclosed.
While cancer subtypes identified in the setting of metastatic urothelial carcinoma have been associated with disease risk and potential therapeutic response, there is a paucity of such characterization in the area of NMIBC to potentially inform clinical decision making.
The application of GeneCentric's RNA-based gene-expression signatures have potential to identify relevant NMIBC subtypes and markers of response to potential therapeutic options. FGFR genomic alterations are among the more common tumor mutations in these patients.
Specifically, the research collaboration aims to deepen tumor genomic and immune microenvironment insights in the setting NMIBC patients utilising GeneCentric's RNA-based tumor bioinformatics technology, including the Bladder Cancer Subtype Profiler (BCSP), pan-cancer diagnostics, cancer antigen discovery, immunogenomic biomarkers, and prototype FGFR activation gene signatures.
GeneCentric Therapeutics, Inc., based in Research Triangle Park, N.C., is an RNA-based genomic solutions provider.
The company's technologies are designed to parse the complexity of tumor and immune biology to discover and develop signatures of responder populations to oncology drugs.
GeneCentric is commercializing its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics companies in applications throughout pre-clinical testing, clinical drug development and commercialization lifecycle phases.
In addition to bladder cancer, GeneCentric has gene expression-based Cancer Profilers for lung, head and neck, pancreatic, kidney, glioblastoma, melanoma and multiple myeloma, as well as signatures to characterise therapeutic cancer targets such as PD(L)-1, PARP, FGFR2/3, and specific cytokines.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma